Oxford vaccine trial result encouraging

DY365
DY365
Published: July 20,2020 10:09 PM
DY365

Story highlights

July 20, 2020: The Oxford University brings rays of hope amidst the COVID-19 scare. The University reveals that the human trials of its vaccine have brought wonderful results.

July 20, 2020: The Oxford University brings rays of hope amidst the COVID-19 scare. The University reveals that the human trials of its vaccine have brought wonderful results. 



"ChAdOx1 nCoV-19 showed an acceptable safety profile, and homologous boosting increased antibody responses. These results, together with the induction of both humoral and cellular immune responses, support large-scale evaluation of this candidate vaccine in an ongoing phase 3 programme," said the university in a research paper.





The findings have been also shared by Assam Health Minister Dr. Himanta Biswa Sharma.





The university found that "ChAdOx1nCoV-19 was safe, tolerated, and immunogenic, while reactogenicity was reduced with paracetamol. A single dose elicited both humoral and cellular responses against SARS-CoV-2, with a booster immunisation augmenting neutralising antibody titres. The preliminary results of this first-in-human clinical trial supported clinical development progression into ongoing phase 2 and 3 trials. Older age groups with comorbidities, health-care workers, and those with higher risk for SARS-CoV-2 exposure are being recruited and assessed for efficacy, safety, and immunogenicity of ChAdOx1 nCoV-19 given as a single-dose or two-dose administration regimen in further trials conducted in the UK and overseas. We will also evaluate the vaccine in children, once sufficient safety data have been accumulated in adult studies. Phase 3 trials are now underway in Brazil, South Africa, and the UK and will evaluate vaccine efficacy in diverse populations."